The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | Clinical updates on the use of ropeginterferon for polycythemia vera
Richard Silver, MD, Weill Cornell Medical College, New York, NY, discusses the structure and use of ropeginterferon for the treatment of polycythemia vera, outlining its mechanism of action which allows for its administration every two to four weeks. Prof. Silver highlights the benefits of ropeginterferon therapy, and compares it to other interferon therapies which have also shown promise. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Richard Silver, MD, has participated in speakers’ bureau with PharmaEssentia and consultancy with AbbVie.
